le Coutre P, Bock S, Jakse G, Petrides P E
Department of Medicine III, University of Munich Medical School Grosshadern, FRG.
Urol Res. 1992;20(4):293-6. doi: 10.1007/BF00300262.
A specific heterogeneous enzyme-linked immunosorbent assay (ELISA) has been established in order to determine levels of low-molecular-weight epidermal growth factor (EGF) in the urine of patients with renal cell carcinoma who had undergone unilateral radical nephrectomy. Urine specimens, i.e., 20 pre- and postsurgical specimens from a group of patients and 22 from a control group, were assayed after the urine had been freed from high-molecular-weight proteins (greater than 30 kDa) and salts. EGF levels were expressed as urinary EGF/creatinine ratios, and a highly significant decrease (alpha = 0.0005 by Student's t-test) of urinary EGF was found in the patient group prior to surgery. The cancer patients also showed an additional loss of urinary EGF after unilateral nephrectomy (alpha = 0.0005 by Student's t-test). These data correlate with our previous findings that pro-EGF gene expression is decreased in human renal carcinoma and support the concept that low-molecular-weight urinary EGF is derived from high-molecular-weight kidney pro-EGF.
为了测定接受单侧根治性肾切除术的肾细胞癌患者尿液中低分子量表皮生长因子（EGF）的水平，已建立了一种特定的异质酶联免疫吸附测定（ELISA）方法。对一组患者的20份术前和术后尿液标本以及22份对照组尿液标本在去除高分子量蛋白质（大于30 kDa）和盐类后进行检测。EGF水平以尿EGF/肌酐比值表示，术前患者组尿EGF显著降低（经学生t检验，α = 0.0005）。癌症患者在单侧肾切除术后尿EGF也出现额外丢失（经学生t检验，α = 0.0005）。这些数据与我们之前的发现相关，即人肾癌中前EGF基因表达降低，并支持低分子量尿EGF来源于高分子量肾前EGF的概念。
